Calidi Biotherapeutics Statistics
Total Valuation
CLDI has a market cap or net worth of $3.48 million. The enterprise value is $1.35 million.
| Market Cap | 3.48M |
| Enterprise Value | 1.35M |
Important Dates
The last earnings date was Thursday, August 13, 2026, after market close.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CLDI has 2.59 million shares outstanding. The number of shares has increased by 537.31% in one year.
| Current Share Class | 2.58M |
| Shares Outstanding | 2.59M |
| Shares Change (YoY) | +537.31% |
| Shares Change (QoQ) | +119.79% |
| Owned by Insiders (%) | 0.75% |
| Owned by Institutions (%) | 1.39% |
| Float | 2.56M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.89 |
| P/TBV Ratio | 1.11 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.68, with a Debt / Equity ratio of 0.62.
| Current Ratio | 1.68 |
| Quick Ratio | 1.34 |
| Debt / Equity | 0.62 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -69.73 |
Financial Efficiency
Return on equity (ROE) is -672.22% and return on invested capital (ROIC) is -199.91%.
| Return on Equity (ROE) | -672.22% |
| Return on Assets (ROA) | -134.79% |
| Return on Invested Capital (ROIC) | -199.91% |
| Return on Capital Employed (ROCE) | -449.99% |
| Weighted Average Cost of Capital (WACC) | 11.16% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$808,793 |
| Employee Count | 29 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, CLDI has paid $17,000 in taxes.
| Income Tax | 17,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -95.13% in the last 52 weeks. The beta is 1.33, so CLDI's price volatility has been higher than the market average.
| Beta (5Y) | 1.33 |
| 52-Week Price Change | -95.13% |
| 50-Day Moving Average | 2.02 |
| 200-Day Moving Average | 9.63 |
| Relative Strength Index (RSI) | 35.12 |
| Average Volume (20 Days) | 310,833 |
Short Selling Information
The latest short interest is 231,318, so 8.92% of the outstanding shares have been sold short.
| Short Interest | 231,318 |
| Short Previous Month | 267,251 |
| Short % of Shares Out | 8.92% |
| Short % of Float | 9.02% |
| Short Ratio (days to cover) | 0.55 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -17.85M |
| Pretax Income | -17.49M |
| Net Income | -23.46M |
| EBITDA | -16.14M |
| EBIT | -17.85M |
| Earnings Per Share (EPS) | -$33.30 |
Balance Sheet
The company has $4.07 million in cash and $1.94 million in debt, with a net cash position of $2.13 million or $0.82 per share.
| Cash & Cash Equivalents | 4.07M |
| Total Debt | 1.94M |
| Net Cash | 2.13M |
| Net Cash Per Share | $0.82 |
| Equity (Book Value) | 3.13M |
| Book Value Per Share | 1.50 |
| Working Capital | 2.19M |
Cash Flow
In the last 12 months, operating cash flow was -$18.28 million and capital expenditures -$118,000, giving a free cash flow of -$18.40 million.
| Operating Cash Flow | -18.28M |
| Capital Expenditures | -118,000 |
| Depreciation & Amortization | 1.40M |
| Net Borrowing | -867,000 |
| Free Cash Flow | -18.40M |
| FCF Per Share | -$7.09 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CLDI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -537.31% |
| Shareholder Yield | -537.31% |
| Earnings Yield | -674.89% |
| FCF Yield | -529.33% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 31, 2026. It was a reverse split with a ratio of 1:16.
| Last Split Date | Jul 31, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:16 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |